Plasma pharmacokinetics of the combination of potassium chloride extended-release tablets and potassium citrate granules in patients with cardiovascular emergencies

Objective To simulate plasma pharmacokinetics (PK) parameters of combining potassium citrate granules and potassium chloride extended-release tablets using real-world data, guiding optimal dosing and timing for cardiovascular emergency patients. Methods A retrospective study analyzed PK characteristics in patients receiving both drugs at Fuwai Yunnan Hospital from January 1 to March 31, 2024, using non-compartmental analysis (NCA). Results Among 330 patients, the T max values for 1-dose, 2-dose, and 3-dose administrations were 4.65 h, 6.00 h, and 6.11 h. The half-life ( t 1/2 ) was 1.33 h, 13.53 h, and 6.11 h, respectively. Each dose elevated plasma potassium by 0.31 ± 0.05 mmol/L. The limited areas under the plasma curve (AUC limit ) were 30.37 mmol-h/L, 106.89 mmol-h/L, 141.74 mmol-h/L. Co-administered dose and AUC limit were linearly related (R 2 = 0.9554). Conclusion PK data fit a 1-compartment model, supporting safe, rational potassium supplementation in cardiovascular emergencies.